Kurs
-0,91%
Kurs
-0,91%
Open
66,00
High
66,90
Low
62,90
Close
65,40
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Est. tid* | ||
| 2026-02-25 | 07:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-27 | N/A | X-dag ordinarie utdelning NYKD 1.00 NOK |
| 2025-05-26 | N/A | Årsstämma |
| 2025-04-23 | - | Extra Bolagsstämma 2025 |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-11-17 07:00:00
Oslo, Norway, November 17, 2021 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of vaccines
and novel immunotherapies, today announced its third quarter 2021 results.
The third quarter 2021 report will be available at
https://www.vaccibody.com/financial-reports-and-presentations/
Contact for Vaccibody:
CEO Michael Engsig
Vaccibody AS
info@vaccibody.com
About Vaccibody
Vaccibody, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Vaccibody's modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which are
essential for inducing rapid, strong and long-lasting antigen specific immune
responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment
of human papilloma virus 16 induced malignancies which is in Phase 2 for the
treatment of cervical cancer